Contact this trialFirst, we need to learn more about you.
Chemotherapy + Osimertinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Minneapolis, Minnesota
This trial tests a combination of chemotherapy and osimertinib in patients with advanced lung cancer that has spread outside the brain after earlier treatment. Osimertinib blocks a protein that helps cancer grow, and chemotherapy kills cancer cells. Osimertinib has shown improvements in progression-free survival over earlier treatments and is preferred for initial treatment of EGFR-mutant NSCLC.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service